Risks and predictors of the development of psoriatic arthritis in psoriasis and issues of the early administration of genetically engineered biological products

2020 ◽  
Vol 19 (3) ◽  
pp. 289
Author(s):  
L.S. Kruglova ◽  
A.N. Lvov ◽  
A.V. Pushkina
Keyword(s):  
Psoriatic Arthritis ◽  
Genetically Engineered ◽  
Early Administration ◽  
Biological Products

scholarly journals Implementation of the principle of sale and purchase transactions through MLM in Brand Branch (BC) PT. Herba Penawar Alwahida Indonesia (HPAI) Tanjungbalai

2020 ◽  
Vol 3 (4) ◽  
pp. 3376-3385
Author(s):  
Asmuni Asmuni ◽  
Syahnan Syahnan ◽  
Asyura Asyura
Keyword(s):  
Food Product ◽  
Genetically Engineered ◽  
Certification Process ◽  
Product Certification ◽  
Biological Products ◽  
The Public ◽  
Long Time ◽  
Chemical Products ◽  
Used Goods ◽  
Current Reality

Products are "goods and / or services related to food, beverages, drugs, cosmetics, chemical products, biological products, genetically engineered products, as well as used goods that are used, used or utilized by the public", while the halal certificate is a certificate issued by the Central or Provincial MUI regarding the case of a food product, foodstuff, beverage and medicine and cosmetics produced by the company after being examined and declared halal by an institution authorized to issue a halal product certification. In Article 4 of Law No. 33 of 2014 concerning the guarantee of halal products it states that "Products that enter, circulate and are traded in the territory of Indonesia must be certified halal". Normatively, the article clearly stipulates that drugs that enter, circulate and are traded in the territory of Indonesia must be guaranteed halal. However, the halal certification process for medicines in Indonesia is waiting for a long time due to various dynamics, this is the content of researchers seeing the gap between Law Number 33 of 2014 and the current reality, we should be able to reflect on other countries as well. Which is more advanced than Indonesia regarding halal certification?

scholarly journals Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis

2021 ◽  
Vol 11 (3) ◽  
pp. 225-228
Author(s):  
V. V. Didenko ◽  
G. A. Kalashnik ◽  
Ju. Ju. Karpenko ◽  
E. N. Harlamova
Keyword(s):  
Psoriatic Arthritis ◽  
Medical History ◽  
Retrospective Analysis ◽  
Clinical Case ◽  
Genetically Engineered ◽  
History Of

This article considers the relevance of treating psoriatic arthritis with genetically engineered drugs such as adalimumab and secukinumab. Also, it conducts retrospective analysis of the medical history of the patient, who had this therapy.

scholarly journals Targeted anti-inflammatory therapy effect on various indicators of the psoriatic arthritis activity: Moscow Unified Arthritis Registry (MUAR) data

2021 ◽  
Vol 5 (2) ◽  
pp. 78-83
Author(s):  
K.A. Lytkina ◽  
◽  
G.V. Lukina ◽  
E.N. Koltsova ◽  
E.I. Shmidt ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Certolizumab Pegol ◽  
Genetically Engineered ◽  
Targeted Drugs ◽  
Biological Drugs ◽  
Synthetic Drugs ◽  
Das 28 ◽  
Therapy Effect ◽  
Anti Inflammatory ◽  
The Impact

Background: the number of genetically engineered biological drugs and targeted synthetic drugs for the treatment of psoriatic arthritis (PA) is rapidly increasing. Data on their comparative efficacy is limited. The results of individual studies suggest that the drugs may show different efficacy concerning different disease manifestations (arthritis, spondylitis, entesitis, cutaneous and nail lesions). Aim: to compare the effect of targeted drugs on the results achieved in different PA domains in real clinical practice. Patients and Methods: the data were taken from the Moscow Unified Arthritis Registry (MUAR). We analyzed treatment episodes in which there was a completed visit no earlier than 6 months from therapy initiation with targeted drug (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, tofacitinib, ustekinumab). Drug comparison was carried out according to the achieved values of the DAS-28, BASDAI, MASES, LEI, DLQI, PASI and BSA indices. The most significant confounders (factors that characterize the patient and are significantly related to the studied indicator) were established for each group of indicators to eliminate the impact of differences between patients who received different drugs. The comparisons were adjusted for confounders. Results: the analysis included 184 treatment episodes with targeted drugs in 156 patients with PA. There were no significant differences between the drugs in their effect on the following domains: «joints» domain (DAS-28), «spine/entheses» domain (BASDAI, MASKS, LEI), «skin» domain (DLQI, PASI, BSA). Conclusion: the achieved values of activity indicators concerning the involvement of joint, spine, entheses and skin in patients with PA didn’t significantly differ when treated with various targeted drugs. KEYWORDS: psoriatic arthritis, enthesitis, spondylitis, sacroiliitis, targeted therapy, treatment efficacy, confounder. FOR CITATION: Lytkina K.A., Lukina G.V., Koltsova E.N. et al. Targeted anti-inflammatory therapy effect on various indicators of the psoriatic arthritis activity: Moscow Unified Arthritis Registry (MUAR) data. Russian Medical Inquiry. 2021;5(2):78–83. DOI: 10.32364/2587-6821- 2021-5-2-78-83.

scholarly journals Psoriasis and inflammatory bowel diseases: pathogenetic pathways and the choice of biologic therapy (a literature review)

2019 ◽  
Vol 47 (6) ◽  
pp. 568-578 ◽  
Author(s):  
L. S. Kruglova ◽  
A. N. Lvov ◽  
A. V. Kagramanova ◽  
O. V. Knyazev
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Psoriatic Arthritis ◽  
Crohn's Disease ◽  
Genetically Engineered ◽  
Evidence Level ◽  
Frequent Administration ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Effector Cytokines

Psoriasis and inflammatory bowel disease (IBD) are multifactorial chronic immuno-inflammatory potentially disabling disorders with similar genetic factors and immunological pathways, in particular, genetic polymorphisms of IL-23R, which determines the signal IL-12/23-mediated pathway of immunopathogenesis. The emergence of genetically engineered biological agents has changed the prognosis for both psoriasis and IBD. The intersection of the therapeutic spectrum in psoriasis and IBD is a very important point when choosing the management strategy for these patients. Infliximab and adalimumab are effective in the treatment of psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis (evidence level 1A). Ustekinumab demonstrates effectiveness in the treatment of psoriasis, psoriatic arthritis (evidence level 1A) and Crohn's disease (evidence level 1B). Etanercept and secukinumab have been shown to be effective against psoriasis, psoriatic arthritis (evidence level 1A) and ineffective and even associated with exacerbation risk in Crohn's disease and ulcerative colitis. Inhibition of regulatory cytokines IL-12/23 also has a number of advantages compared to the blockade of effector cytokines (TNF-α, IL-17) due to potentially long-term and stable treatment results and less frequent administration.

scholarly journals EXPERIENCE OF THE LONG-TERM USE OF ANTICYTOKINE THERAPY IN PSORIASIS

2017 ◽  
Vol 20 (3) ◽  
pp. 163-166
Author(s):  
Violetta A. Kovtunova ◽  
V. V Dumchenko ◽  
E. G Bakhmutova ◽  
T. A Tkachenko ◽  
E. Yu Yanchevskaya ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Therapeutic Response ◽  
Biological Therapy ◽  
Combined Therapy ◽  
Severe Form ◽  
Genetic Characteristics ◽  
Biological Products ◽  
Factor Α ◽  
And Control

Increasing the effectiveness of treatment and restoring the quality of life in patients with moderate to severe and severe forms of psoriasis is one of the most important trends in modern dermatology. The appearance of biological products in the late XXth century opened new opportunities in the treatment and control of the course of the disease in patients suffering from moderate and severe forms of psoriasis. Conducting maintenance system treatment with biological products reduces the severity of course of dermatosis, and in some cases prevents the occurrence of disease relapses. Despite the increasing popularity of anti-cytokine drugs, there are difficulties in the treatment of choice of the therapy in some cases. Among the main reasons for the lack of response to ongoing biological therapy are the genetic characteristics of the patient and the immunogenicity of the drugs. Failures in the use of biological therapy can also result a low concentration of the drug before the next administered dose. It has been proven that the combined use of methotrexate and infliximab inhibits the development of anti-drug antibodies that are associated with the development of a low therapeutic response. The article describes the clinical observation of a patient suffering for 20 years from a severe form of psoriasis and psoriatic arthritis. The experience of long-term (about 10 years) prescription of the biological preparation infliximab with sufficient clinical response without additional use of methotrexate is shown. The results of successful combined therapy of psoriatic erythroderma and psoriatic arthritis with infliximab and acitretin in order to reduce the immunogenicity of the tumor necrosis factor α blocker and avoid the ”escape” effect are described. The data of restoration of a good therapeutic response to systemic biological therapy with infliximab after administration of acitretin are presented.

scholarly journals Biologic therapies for the treatment of psoriatic arthritis

2021 ◽  
Vol 64 (2) ◽  
pp. 124-129
Author(s):  
Tae-Jong Kim
Keyword(s):  
Psoriatic Arthritis ◽  
Kinase Inhibitors ◽  
Phosphodiesterase Inhibitors ◽  
Janus Kinase ◽  
Interleukin 12 ◽  
Interleukin 17 ◽  
Dramatic Improvement ◽  
Functional Impairments ◽  
Biological Products ◽  
Factor Α

Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease commonly associated with plaque psoriasis that, manifests with peripheral arthritis, dactylitis, enthesitis, and axial involvement. PsA can be progressive and harmful, resulting in joint deformities, functional impairments, low quality of life, and increased mortality. It was found that both non-pharmacologic and pharmacologic treatment could improve conditions of PsA. Recently launched biological products have become the main therapeutic agents used for treating PsA unresponsive to conventional disease modifying anti-rheumatic drugs. This paper aims at introducing available biologics for PsA management in Korea. The tumor necrosis factor-α inhibitor was the first approved biological product to show outstanding efficacy for treating PsA. Ustekinumab, designed for blocking interleukin-12/23, has been approved and widely used. Interleukin-17 inhibitors such as secukinumab and ixekizumab have also been introduced to improve the symptoms of PsA. It was found that many patients with PsA experienced a dramatic improvement in their condition after using these biological products. Additionally, new immunological modulators such as phosphodiesterase inhibitors and Janus kinase inhibitors were approved for the treatment of PsA.

Sign in / Sign up

Export Citation Format

Share Document